Claritev Corporation (CTEV) saw its stock price soar by 11.59% in pre-market trading on Friday following the release of its third-quarter 2025 financial results and an upward revision of its full-year guidance. The healthcare technology company reported better-than-expected revenue growth and a narrower net loss, signaling progress in its transformation efforts.

For the third quarter, Claritev reported revenues of $246.0 million, a 6.7% increase compared to the same period last year, surpassing analysts' expectations of $235.8 million. The company's net loss narrowed significantly to $69.8 million, or $4.23 per diluted share, from $391.5 million in Q3 2024. While the loss per share was higher than the $3.59 analysts had forecast, investors appeared to focus on the overall improvement in financial performance.

Notably, Claritev raised its full-year 2025 revenue growth guidance to 2.8% to 3.2%, up from its previous forecast of flat to 2% growth. This optimistic outlook, coupled with the company's strong Q3 performance, seems to have fueled investor confidence. CEO Travis Dalton stated, "We declared 2025 would be the Year of the Turn at Claritev. Our third quarter results and increased full year guidance demonstrate that we have made the Turn and are now focused on the next phase of our Strategic Plan -- The Way Up." The company's focus on making healthcare more affordable and transparent, along with its success in renewing top clients and expanding its international business, appears to be resonating with the market.